ESTEVE Expands Its US Footprint by Acquiring Regis Technologies to Enhance Service Offerings

ESTEVE Expands Its Reach with the Acquisition of Regis Technologies

In a significant development for the pharmaceutical landscape, ESTEVE has announced its acquisition of Regis Technologies, a prominent Contract Development and Manufacturing Organization (CDMO) based in Chicago, USA. This strategic move is set to bolster ESTEVE's presence in the United States and enhance its offerings in the field of pharmaceutical development and manufacturing.

Expansion of Services and Capabilities

The acquisition allows ESTEVE to broaden its service portfolio in the realm of contract development and manufacturing for small-molecule pharmaceutical active ingredients (APIs). These services encompass the entire pharmaceutical development lifecycle, extending from preclinical stages to commercial manufacturing. This transition not only signifies ESTEVE's physical establishment in the U.S. market but also amplifies the company’s capabilities in delivering innovative solutions to pharmaceutical clients.

For over 65 years, Regis Technologies has been a key player in the API CDMO sector, providing comprehensive services such as process research and development, analytics and stability testing, cGMP API manufacturing, CMC support, and a broad array of chromatography products. Joan Petit, ESTEVE's Chief Industrial Operations Officer, expressed confidence in the acquisition, emphasizing that it strengthens their team and enhances their capabilities to meet the demands of innovative pharmaceutical companies. The move is expected to enrich the ESTEVE CDMO business unit with approximately 70 skilled professionals.

Strategic Importance of the U.S. Market

The U.S. is recognized as a pivotal market for ESTEVE. According to Staffan Schüberg, CEO of ESTEVE, this acquisition is a crucial step towards fulfilling their mission of improving people's lives by expanding their CDMO expertise and delivering an integrated service offering in this key market. The synergy between ESTEVE’s operational ethos and Regis Technologies' long-standing commitment to quality and service is anticipated to generate remarkable value for both companies and their clients.

Scott Aladeen, the President and CEO of Regis Technologies, remarked on the alignment of values between the two organizations, highlighting that both are family-owned entities committed to employee satisfaction and long-term value creation for customers. This shared vision will facilitate a seamless integration process and foster an environment of growth and innovation.

ESTEVE's Commitment to Excellence

As a global pharmaceutical firm, ESTEVE has established itself with a clear objective of enhancing the quality of life through specialized treatments across various therapeutic areas. Founded in 1929 and headquartered in Barcelona, ESTEVE now operates significant pharmaceutical subsidiaries in multiple countries, including Spain, Portugal, Italy, Germany, France, the UK, and the USA.

The company’s commitment to providing advanced CDMO services is complemented by its focus on developing specialized medicines that address unmet medical needs in diverse therapeutic fields. Additionally, ESTEVE emphasizes adhering to its core values of human-centric operations, transparency, and accountability in all of its endeavors.

In summary, ESTEVE’s acquisition of Regis Technologies marks a transformative milestone for the company, positioning it to serve its U.S.-based clientele more effectively and broadening its pharmaceutical development capabilities globally. This strategic expansion is also indicative of the ongoing evolution within the pharmaceutical manufacturing landscape, where adaptability and innovation remain critical to success.

About ESTEVE

ESTEVE operates across multiple production sites globally, including facilities in Spain, Mexico, China, and now the United States. The company’s dual focus on CDMO services and proprietary pharmaceutical products reinforces its intent to deliver exceptional value within the pharmaceutical industry.

With the integration of Regis Technologies, ESTEVE is poised to continue its legacy of excellence in drug development and manufacturing, promoting advancements that contribute to enhanced healthcare outcomes worldwide.